Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Drug Design, Development and Therapy|March 2, 2026
Beyond Oncogenes: Selectively Targeting Whole-Tumor Cell Growth RegulationAlbert Qin
Frontiers in Oncology|May 14, 2023
An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1Albert Qin
International Journal of Hematology|July 1, 2024
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2bKazuya Shimoda, Albert Qin, Norio Komatsu, et al.
Clinical Drug Investigation|March 16, 2021
Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous AdministrationNarihisa Miyachi, Oleh Zagrijtschuk, Lisa Kang, et al.
Viruses|June 24, 2022
Novel Pegylated Interferon for the Treatment of Chronic Viral HepatitisYi-Wen Huang, Albert Qin, Chan-Yen Tsai, et al.
Frontiers in Oncology|February 13, 2023
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the futureAlbert Qin, Raymond W Urbanski, Lennex Yu, et al.
International Journal of Molecular Sciences|January 11, 2024
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical ResultsAlbert Qin, Chang-Ru Wu, Ming-Chih Ho, et al.
Hepatology International|April 5, 2025
Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trialAlbert Qin, Ming-Chih Ho, Chan-Yen Tsai, et al.
Advances in Therapy|November 27, 2023
Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with ComorbiditiesWang-Da Liu, Hsin-An Hou, Ko-Jen Li, et al.
Current Hematologic Malignancy Reports|October 8, 2025
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia VeraMinghui Duan, Prithviraj Bose, Anthony M Hunter, et al.
Pageof 5